Preclinical biomarkers of parkinson disease

Archives of Neurology

Volumn 68, Issue 1, 2011, Pages 22-30

  Wu, Yuncheng ^a,b   Le, Weidong ^b   Jankovic, Joseph ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANOSMIA; CONSTIPATION; DISEASE COURSE; DISEASE PREDISPOSITION; DYSAUTONOMIA; ECHOGRAPHY; ESSENTIAL TREMOR; EYE MOVEMENT DISORDER; HUMAN; LEWY BODY; MOOD DISORDER; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; SYMPTOM;

ANIMALS; BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; GENETIC MARKERS; HUMANS; PARKINSON DISEASE;

EID: 78651315861     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.321     Document Type: Review

References (100)

1. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464-474.
2. Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol. 2009;66(2):167-172.
3. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.
4. Tolosa E, Gaig C, Santamaría J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology. 2009;72(7)(suppl):S12-S20.
5. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006;26(9):1198-1212.
6. Greffard S, Verny M, Bonnet AM, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol. 2006;63(4):584-588.
7. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005;62(3):378-382.
8. Marek K, Jennings D. Can we image premotor Parkinson disease? Neurology. 2009;72(7)(suppl):S21-S26.
9. Siderowf A, Stern MB. Preclinical diagnosis of Parkinson's disease: are we there yet? Curr Neurol Neurosci Rep. 2006;6(4):295-301.
10. Jankovic J. Progression of Parkinson disease: are we making progress in charting the course? Arch Neurol. 2005;62(3):351-352.
11. Hawkes CH. The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it? Mov Disord. 2008;23(13):1799-1807.
12. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999;45(5):577-582.
13. Laihinen A, Ruottinen H, Rinne JO, et al. Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J Neurol. 2000;247(suppl 2):II110-II113. doi:10.1007/PL00022911.
14. Le W, Chen S, Jankovic J. Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist. 2009;15(1):28-35.
15. Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5(3):235-245.
16. Siderowf A, Stern MB. Premotor Parkinson's disease: clinical features, detection, and prospects for treatment. Ann Neurol. 2008;64(suppl 2):S139-S147. doi: 10.1002/ana.21462.
17. Louis ED, Frucht SJ. Prevalence of essential tremor in patients with Parkinson's disease vs Parkinson-plus syndromes. Mov Disord. 2007;22(10):1402-1407.
18. Fekete R, Jankovic J. Revisiting the relationship between essential tremor and Parkinson's disease. Mov Disord. In press.
19. Louis ED, Faust PL, Vonsattel JP, et al. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain. 2007;130(pt 12):3297-3307.
20. Minen MT, Louis ED. Emergence of Parkinson's disease in essential tremor: a study of the clinical correlates in 53 patients. Mov Disord. 2008;23(11):1602-1605.
21. Hedera P, Fang JY, Phibbs F, Cooper MK, Charles PD, Davis TL. Positive family history of essential tremor influences the motor phenotype of Parkinson's disease. Mov Disord. 2009;24(15):2285-2288.
22. Benito-León J, Louis ED, Bermejo-Pareja F; Neurological Disorders in Central Spain Study Group. Risk of incident Parkinson's disease and parkinsonism in essential tremor: a population based study. J Neurol Neurosurg Psychiatry. 2009;80(4):423-425.
23. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord. 2007;22(6):839-842.
24. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol. 2008;63(2):167-173.
25. Silveira-Moriyama L, Petrie A, Williams DR, et al. The use of a color coded probability scale to interpret smell tests in suspected parkinsonism. Mov Disord. 2009;24(8):1144-1153.
26. Goldstein DS, Holmes C, Bentho O, et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord. 2008;14(8):600-607.
27. Witt M, Bormann K, Gudziol V, et al. Biopsies of olfactory epithelium in patients with Parkinson's disease. Mov Disord. 2009;24(6):906-914.
28. Monderer R, Thorpy M. Sleep disorders and daytime sleepiness in Parkinson's disease. Curr Neurol Neurosci Rep. 2009;9(2):173-180.
29. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72(15):1296-1300.
30. Gagnon JF, Vendette M, Postuma RB, et al. Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. Ann Neurol. 2009;66(1):39-47.
31. Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov Disord. 2008;23(12):1665-1672.
32. Michell AW, Xu Z, Fritz D, et al. Saccadic latency distributions in Parkinson's disease and the effects of L-dopa. Exp Brain Res. 2006;174(1):7-18.
33. Blekher T, Weaver M, Rupp J, et al. Multiple step pattern as a biomarker in Parkinson disease. Parkinsonism Relat Disord. 2009;15(7):506-510.
34. Evatt ML, Chaudhuri KR, Chou KL, et al. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation: critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord. 2009;24(5):635-646.
35. Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord. 2009;15(suppl 3):S224-S232.
36. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson's disease. Mov Disord. 2010;25(1):2-12.
37. Aarsland D, Brønnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry. 2009;80(8):928-930.
38. Ravina B, Elm J, Camicioli R, et al. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009;24(9):1306-1311.
39. Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69(4):342-347.
40. Ishihara L, Brayne C. What is the evidence for a premorbid parkinsonian personality: a systematic review. Mov Disord. 2006;21(8):1066-1072.
41. Evans AH, Lawrence AD, Potts J, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry. 2006;77(3):317-321.
42. Macías Y, Benito-León J, Louis ED, Cano-Vindel A. Anger in Parkinson's disease: a case-control study. Mov Disord. 2008;23(2):195-199.
43. Abe N, Fujii T, Hirayama K, et al. Do parkinsonian patients have trouble telling lies? the neurobiological basis of deceptive behaviour. Brain. 2009;132(pt 5):1386-1395.
44. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211.
45. Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol. 2008;64(5):485-491.
46. Lees AJ. The Parkinson chimera. Neurology. 2009;72(7)(suppl):S2-S11.
47. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of α-synuclein staging. Neuropathol Appl Neurobiol. 2008;34(3):284-295.
48. Dickson DW, Fujishiro H, DelleDonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 2008;115(4):437-444.
49. Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008;115(4):399-407.
50. Attems J, Jellinger KA. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease. Neuropathol Appl Neurobiol. 2008;34(4):466-467.
51. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A. 2009;106(31):12571-12572.
52. DelleDonne A, Klos KJ, Fujishiro H, et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol. 2008;65(8):1074-1080.
53. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007;33(6):599-614.
54. Probst A, Bloch A, Tolnay M. New insights into the pathology of Parkinson's disease: does the peripheral autonomic system become central? Eur J Neurol. 2008;15(suppl 1):1-4.
55. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, et al. Do α-synuclein aggregates in autonomic plexuses predate Lewy body disorders? a cohort study. Neurology. 2007;68(23):2012-2018.
56. Spiegel J, Hellwig D, Farmakis G, et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord. 2007;22(7):1004-1008.
57. Michell AW, Luheshi LM, Barker RA. Skin and platelet α-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci Lett. 2005;381(3):294-298.
58. Shishido T, Ikemura M, Obi T, et al. α-Synuclein accumulation in skin nerve fibers revealed by skin biopsy in pure autonomic failure. Neurology. 2010;74(7):608-610.
59. Marek K, Jennings D, Tamagnan G, Seibyl J. Biomarkers for Parkinson's disease: tools to assess Parkinson's disease onset and progression [published correction appears in Ann Neurol. 2009;65(2):232]. Ann Neurol. 2008;64(suppl 2):S111-S121.
60. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009;72(16):1378-1384.
61. Stoessl AJ. Positron emission tomography in premotor Parkinson's disease. Parkinsonism Relat Disord. 2007;13(suppl 3):S421-S424.
62. Booij J, Knol RJ. SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. Parkinsonism Relat Disord. 2007;13(suppl 3):S425-S428.
63. Schwingenschuh P, Ruge D, Edwards MJ, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord. 2010;25(5):560-569.
64. Panzacchi A, Moresco RM, Garibotto V, et al. A voxel-based PET study of dopamine transporters in Parkinson's disease: relevance of age at onset. Neurobiol Dis. 2008;31(1):102-109.
65. Zecca L, Berg D, Arzberger T, et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord. 2005;20(10):1278-1285.
66. Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 2008;7(11):1044-1055.
67. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology. 2008;70(16, pt 2):1411-1417.
68. Nandhagopal R, Mak E, Schulzer M, et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology. 2008;71(22):1790-1795.
69. Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M. Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. CNS Neurosci Ther. 2009;15(2):157-182.
70. Mollenhauer B, Trenkwalder C. Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord. 2009;24(10):1411-1426.
71. Gasser T. Genomic and proteomic biomarkers for Parkinson disease. Neurology. 2009;72(7)(suppl):S27-S31.
72. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. In press. doi:10.1002/ana.22311.
73. Hong Z, Shi M, Chung KA, et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010;133(pt 3):713-726.
74. Aarsland D, Ravina B. Biomarkers of PD progression: is CSF the answer? Neurology. 2010;75(12):1036-1037.
75. Brighina L, Prigione A, Begni B, et al. Lymphomonocyte α-synuclein levels in aging and in Parkinson disease. Neurobiol Aging. 2010;31(5):884-885.
76. Li QX, Mok SS, Laughton KM, et al. Plasma α-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol. 2007;204(2):583-588.
77. Westermann B, Wattendorf E, Schwerdtfeger U, et al. Functional imaging of the cerebral olfactory system in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2008;79(1):19-24.
78. Ascherio A, LeWitt PA, Xu K, et al; Parkinson Study Group DATATOP Investigators. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66(12):1460-1468.
79. Le W, Pan T, Huang M, et al. Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci. 2008;273(1-2):29-33.
80. Scherzer CR, Eklund AC, Morse LJ, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007;104(3):955-960.
81. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain. 2008;131(pt 2):389-396.
82. Hwang H, Zhang J, Chung KA, et al. Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev. 2010;29(1):79-125.
83. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis. 2009;35(2):165-176.
84. Schipper HM, Kwok CS, Rosendahl SM, et al. Spectroscopy of human plasma for diagnosis of idiopathic Parkinson's disease. Biomark Med. 2008;2(3):229-238.
85. Hennecke G, Scherzer CR. RNA biomarkers of Parkinson's disease: developing tool for new therapies. Biomarkers Med. 2008;2(1):41-53.
86. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2006;354(4):424-425.
87. Lesage S, Dürr A, Tazir M, et al; French Parkinson's Disease Genetics Study Group. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006;354(4):422-423.
88. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129(4):526-529.
89. Veeriah S, Taylor BS, Meng S, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other humanmalignancies. Nat Genet. 2010;42(1):77-82.
90. Sutherland G, Mellick G, Sue C, et al. A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. Neurosci Lett. 2007;414(2):170-173.
91. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007;166(5):561-567. (Pubitemid 47283643)
92. Schwarzschild MA, Schwid SR, Marek K, et al; Parkinson Study Group PRECEPT Investigators. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-723.
93. Schiess M, Oh I. Serum uric acid and clinical progression in Parkinson disease: potential biomarker for nigrostriatal failure. Arch Neurol. 2008;65(6):698-699.
94. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol. 2008;167(1):90-95.
95. Rentzos M, Nikolaou C, Andreadou E, et al. Circulating interleukin-10 and interleukin- 12 in Parkinson's disease. Acta Neurol Scand. 2009;119(5):332-337.
96. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu- Asia Aging Study. Mov Disord. 2008;23(7):1013-1018.
97. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol. 2009;65(1):76-82.
98. Jones R. Biomarkers: casting the net wide. Nature. 2010;466(7310):S11- S12.
99. Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord. 2009;24(5):647-654.
100. van Dijk KD, Teunissen CE, Drukarch B, et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis. 2010;39(3):229-241.